Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, PK, and PD of AD-214 vs AD-2141 in Healthy Volunteers
NCT05062876Phase 1Completed
- Sponsor
- Addpharma, Inc.
- Start
- Nov 2021
- Primary completion
- Mar 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of AD-214 in gastroesophageal reflux disease (GERD) (2 arms), sponsored by Addpharma, Inc. Primary endpoints: Area under the plasma drug concentration-time curve at steady state over the dosing interval at Day 29 and Change of integrated gastric acidity at Day 28. Started Nov 2021; status: completed.
02
Drugs
AD-214
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT05062876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05062876.